Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Holding AKBA?
Track your performance easily
AKBA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.80 - $2.48
Previous Close$1.86
Volume513.30K
Average Volume (3M)2.02M
Market Cap
$403.64M
Enterprise Value$412.91M
Total Cash (Recent Filing)$34.02M
Total Debt (Recent Filing)$43.29M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 12, 2025EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding218,181,202
10 Day Avg. Volume2,294,991
30 Day Avg. Volume2,024,929
Standard Deviation0.30
R-Squared0.01
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-8.09
Price to Sales (P/S)2.38
Price to Cash Flow (P/CF)-15.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit3.43
Enterprise Value/Ebitda-462.90
Forecast
1Y Price Target
$5.50Price Target Upside195.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Akebia Therapeutics News
PremiumCompany Announcements
Akebia Therapeutics Prepares for Vafseo Launch
PremiumCompany Announcements
Akebia Therapeutics Secures Supply Agreement for VafseoBulls Say, Bears Say
Bulls Say
Market ReadinessAkebia is well-prepared for a successful launch with rapid uptake and adoption of Vafseo by dialysis organizations.
Regulatory AchievementsThe CMS has granted TDAPA designation for Vafseo, making it eligible to receive additional reimbursement on top of the ESRD bundled rate for two years starting 1/1/2025.
Strategic PartnershipsAkebia announced a multi-year commercial supply agreement with U.S. Renal Care (USRC), the fastest-growing U.S. dialysis provider serving over 36,000 kidney disease patients across 32 states.
Bears Say
Financial ConstraintsThe inability to raise sufficient capital at reasonable terms is considered a risk to the investment thesis and target price.
Market LimitationsThere is a risk of a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing.
Regulatory ChallengesFailure to secure TDAPA designation for Vafseo and additional regulatory requirements could cause significant timeline delays.
---
Ownership Overview
11.59% Insiders
7.73% Mutual Funds
4.38% Other Institutional Investors
66.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.80 and its highest was $2.48 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Mar 12, 2025 which is in 77 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.037.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -$0.07.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 218,181,200 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went down -7%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at N/A.
---
Akebia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (195.70% Upside)
$5.50 (195.70% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 57.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.85%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AKBA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong momentum and strategic positioning for the U.S. launch of Vafseo, with positive engagement from the kidney community and successful reimbursement measures. Despite decreased revenue from Auryxia and an increased net loss, the financial outlook and cash position remain stable.Read More>---
AKBA Stock 12 Month Forecast
Average Price Target
$5.50
▲(195.70% Upside)
Technical Analysis
Best Analysts Covering AKBA
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+5.94%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +5.94% per trade.
---